ABOUT US

A global leader in innovative genomic
technology and diagnostic tests.


What’s new at Agendia?

Get the latest updates on our company and products, as well as new developments in genomic science.

News

In the News

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

News

Media Releases

Agendia Studies Reveal the Influence of Race on a Tumor’s Biology, Reinforcing its Commitment to Advancing Research of Racial Disparities in Breast Cancer

May 31st, 2023|

At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, reinforces its commitment to progressing research of racial disparities in breast cancer through two poster presentations.

Read More

Agendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer

May 31st, 2023|

At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, will present data that proves MammaPrint can predict chemotherapy sensitivity in women with early-stage, HR+HER- breast cancer.

Read More

Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer

March 16th, 2023|

Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapyTrial reinforces Agendia’s progress in developing practice-changing evidence to improve personalized cancer careMarch 16, 2023 Read More

Updated NCCN® Guidelines Recognize MammaPrint® UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates

February 13th, 2023|

Includes level one evidence that MammaPrint can help prevent unnecessary chemotherapy¹ and endocrine therapy² Confirms Agendia’s unique ability to identify tumors that have a very low risk of distant metastasis which can have implications for Read More